I was surprised to learn through my research that Gliclazide also provides some CVE friendly support similar to Metformin. This may be due to its benefits which are mainly for T2DM, and is not yet prescribable for T1D or other insulin dependants.
By the same token I am taking Gymnema Sylvestre which is a herbal supplement that also is claimed to have CVE protection. Again it is better suited for T2DM, and is also not recognised by the medical profession, but has an extensive track record on the Asian Continent. As with all herbal remedies, Caveat Emptor since quality control is not always to the fore, and some suppliers are better thn others. There are no scienctific studies covering its use so the evidence is anecdotal.
There are other supplemt type pills on the market that also make these claims, but with weaker anecdotal support for those claims. I do not use them so cannot comment further.
I think that the problem for T1D is that these 'alternatives' are basically T2D meds, and operate on the pancreas so like all claims for 'protection;' then there is no upfront proof that they work. It requires long term studies to be carried out and generally requires ambulance following to make the connections to CVE. It also requires larger scale data collection than most meds so is not often covered. It helps that in the UK now, new drugs entering the market only get their licences when they have provided evidence of safety for heart conditions, something that came into the selection process following the Avandia / Actos scandal.